Invention Grant
- Patent Title: 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
-
Application No.: US15772887Application Date: 2016-11-02
-
Publication No.: US10556901B2Publication Date: 2020-02-11
- Inventor: Matthew Colin Thor Fyfe
- Applicant: Topivert Pharma Limited
- Applicant Address: GB London
- Assignee: Topivert Pharma Limited
- Current Assignee: Topivert Pharma Limited
- Current Assignee Address: GB London
- Agency: McCarter & English, LLP
- Agent Steven G. Davis; Wei Song
- Priority: GB1519382.4 20151103; GB1606971.8 20160421
- International Application: PCT/GB2016/053392 WO 20161102
- International Announcement: WO2017/077288 WO 20170511
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61P27/02 ; A61P11/06 ; A61P29/00
![4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors](/abs-image/US/2020/02/11/US10556901B2/abs.jpg.150x150.jpg)
Abstract:
There are provided compounds of formula I, wherein X, Ak, s, A, R1 and R2 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of the JAK family) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
Public/Granted literature
Information query